EAM
CBAY

Eagle Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Eagle Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,867
Closed -$21K – 691
2020
Q4 		$21K Buy
+3,867
New +$29.3K ﹤0.01% 556
2019
Q4 		– Sell
-2,334,861
Closed -$12M – 662
2019
Q3 		$12M Sell
2,334,861
-438,790
-16% -$2.66M 0.06% 281
2019
Q2 		$19.9M Sell
2,773,651
-237,972
-8% -$2.69M 0.1% 232
2019
Q1 		$40M Buy
3,011,623
+158,650
+6% +$1.69M 0.21% 181
2018
Q4 		$22.5M Buy
2,852,973
+8,207
+0.3% +$78.1K 0.14% 212
2018
Q3 		$31.5M Buy
2,844,766
+781,700
+38% +$9.71M 0.15% 210
2018
Q2 		$27.7M Buy
+2,063,066
New +$25.8M 0.15% 211

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Eagle Asset Management's CBAY Position: Q1 2021 in Review

Eagle Asset Management sold out of Cymabay Therapeutics (CBAY) in Q1 2021, closing a stake of 3,867 shares — an estimated $21K sold.

Eagle Asset Management first reported a position in CBAY in Q2 2018 and held it in 7 quarters. The position peaked at $40M in Q1 2019. 130 funds tracked by Wall St. Rank hold CBAY as of Q1 2021.

  • Eagle Asset Management reported no remaining Cymabay Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Eagle Asset Management sold 3,867 Cymabay Therapeutics shares in Q1 2021, an estimated $21K.
  • Eagle Asset Management first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 7 quarters.
  • Eagle Asset Management's Cymabay Therapeutics position peaked at $40M in Q1 2019.
  • 130 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2021.

Based on Eagle Asset Management's 13F filing for Q1 2021, filed 14 May 2021.